AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Elahere (mirvetuximab soravtansine) by Quarter
Elahere (mirvetuximab soravtansine) — Worldwide operational (constant-currency) growth YoY (%) (%)
AbbVie Elahere (mirvetuximab soravtansine): 31.8% in Q2 2026, up 8.1 pts from a year earlier.
Where the Q2 2026 figure comes from
“| 31.8”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Elahere (mirvetuximab soravtansine) — Worldwide operational (constant-currency) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 31.8% | +8.1 pts | Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 8.3% | – | Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 21.3% | – | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 22.4% | – | Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗ |
| Q2 2025 | Jun 30, 2025 | 23.7% | – | Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗ |
Cite this data
StockData. (2026). AbbVie Elahere (mirvetuximab soravtansine) (%), quarterly Q2 2025–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/elahere-ww-op-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.